|
You are here: Home: BCU 6|2002: Joyce
O'Shaughnessy, MD: Select publications
Capecitabine: Recent publications
Ahn Sr, JH et al. Phase II study of a combination chemotherapy
of capecitabine and vinorelbine in metastatic breast cancer with
previous exposure to anthracycline and taxane: Preliminary results.
Proc ASCO 2002;Abstract
2030.
Blum JL. The role of capecitabine, an oral, enzymatically
activated fluoropyrimidine, in the treatment of metastatic breast
cancer. Oncologist 2001;6(1):56-64. Abstract
Cassata A et al. Capecitabine: Indications and future
perspectives in the treatment of metastatic colorectal and breast
cancer. Tumori 2001;87(6):364-71. Abstract
Chan SC et al. A phase II study on an all-oral regimen
of capecitabine (XelodaTM) (X), idarubicin (I) and cyclophosphamide
(C) (XIC) for metastatic breast cancer - safety, efficacy and quality
of life. Proc ASCO 2002;Abstract
2023.
Cunningham D, Coleman R. New options for outpatient chemotherapy
— the role of oral fluoropyrimidines. Cancer Treat
Rev 2001;27(4):211-20. Abstract
Donaldson LA et al. A phase I/II study of carboplatin,
vinorelbine and capecitabine in patients with metastatic breast
cancer. Proc ASCO 2002;Abstract
1960.
Fujimoto-Ouchi K et al. Antitumor activity of combinations
of anti-HER-2 antibody trastuzumab and oral fluoropyrimidines capecitabine/5'-dFUrd
in human breast cancer models. Cancer Chemother Pharmacol
2002;49(3):211-6. Abstract
Fujimoto-Ouchi K et al. Schedule dependency of antitumor
activity in combination therapy with capecitabine/5'-deoxy-5-fluorouridine
and docetaxel in breast cancer models. Clin Cancer Res
2001;7(4):1079-86. Abstract
Fumoleau P et al. Capecitabine (Xeloda) in patients with
advanced breast cancer (ABC), previously treated with anthracyclines
and taxanes: Results of a large phase II study. Proc ASCO
2002;Abstract
247.
Ghosn M et al. Vinorelbine (Navelbine) IV and capecitabine
(vinocap) as front line chemotherapy in metastatic breast cancer
(MBC). Proc ASCO 2002;Abstract
1978.
Gradishar WJ. Clinical status of capecitabine in the treatment
of breast cancer. Oncology (Huntingt) 2001;15(1 Suppl 2):69-71;discussion
72. Abstract
Hess DD et al. Phase I - II trial of capecitabine and
vinorelbine in elderly patients (pts: > 65 y) with metastatic
breast cancer (MBC): SAKK 25 / 99 for the Swiss Group of Clinical
Cancer Research, Berne, Switzerland. Proc ASCO 2002;Abstract
2915.
Hori T et al. A randomized study comparing oral and standard
regimens for metastatic breast cancer. Oncol Rep 2001;8(5):1067-71.
Abstract
Hwang JJ, Marshall JL. Capecitabine: Fulfilling the promise
of oral chemotherapy. Expert Opin Pharmacother 2002;3(6):733-43.
Abstract
Maher JF, Villalona-Calero MA. Taxanes and capecitabine
in combination: Rationale and clinical results. Clin Breast
Cancer 2002;2(4):287-93. Abstract
O'Shaughnessy J. Clinical experience of capecitabine in
metastatic breast cancer. Eur J Cancer 2002;38 Suppl 2:10-4.
Abstract
O'Shaughnessy J et al. Superior survival with capecitabine
plus docetaxel combination therapy in anthracycline-pretreated patients
with advanced breast cancer: Phase III trial results. J
Clin Oncol 2002;20(12):2812-23. Abstract
O'Shaughnessy JA et al. Randomized, open-label, phase
II trial of oral capecitabine (Xeloda®) vs a reference arm of
intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil)
as first-line therapy for advanced/metastatic breast cancer. Ann
Oncol 2001;12:1247-54. Abstract
Semiglazov TY et al. Oral capecitabine (Xeloda) in the
treatment of anthracycline-refractory, anthracycline and docetaxel-refractory
metastatic breast cancer (MBC). Proc ASCO 2002;Abstract
2061.
Talbot DC et al. Randomised, phase II trial comparing
oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced
breast cancer pretreated with anthracyclines. Br J Cancer
2002;86:1367-72. Abstract
Twelves C. Vision of the future: Capecitabine.
Oncologist 2001;6 Suppl 4:35-9. Abstract
|
